Skip to main content

Treatment of pulmonary arterial hypertension (PAH)

Ref-Nr: TA-TM 1148


A new therapy for pulmonary arterial hypertension (PAH) is to be developed.


Pulmonary arterial hypertension (high blood pressure in the lung arteries) is a rare, multifactorial, progressive form of pulmonary hypertension (PH). Untreated, it can lead to right heart failure and premature death.
The key structural alteration of PAH is pulmonary vascular remodeling, which causes increasing thickness and stiffness of pulmonary arteries and as a result, leads to increased pressure.

Bilder & Videos





Our novel treatment approach utilises epigenetic modulation by histone-acetyltransferase inhibition with benzimidazole derivates and aims at the restoration of damaged lung vessel structure and function, and the reversal of remodeling.


The compounds showed strong promise for efficacy within 14 days of treatment in animal models and PCLS, with improved hemodynamic, anti-hypertrophic, anti-proliferative and anti-fibrotic properties.
Focus is on restoration of damaged lung vessel structure and function as well as the reversal of the pulmonary vascular remodeling.
Our fundamentally new treatment approach with epigenetic modification offers, for the first time, a reversal of remodeling.  


  • Treatment of PAH
  • Rare lung diseases


TransMIT Gesellschaft für Technologietransfer mbH

Anouschka Ulherr
0641 946434

Kerkrader Str. 3
35394 Gießen




orphan disease, small-molecule compounds, pulmonary arterial hypertension (PAH), benzimidazole derivates, epigenetic modulation-based therapyOn behalf of its shareholder Justus-Liebig-Universität Giessen, TransMIT GmbH is looking for cooperation partners or licensees for clinical trials and further development worldwide.

Angebot Anbieter-Website

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen